NK cell-based immunotherapies are a promising approach to treating GBM from multiple strategic angles: monoclonal antibody therapy targeting TAAs, immune checkpoints, and pure ADCC; CAR-NK cell therapy and other adoptive NK therapies; and Bi-specific killer cell engagers (BiKEs). Here, CACNA1A is linked to glioblastoma.